Marked clonal shifts were noted to occur in nearly one-third of high-risk CLL treated with Ib; greater chance of secondary resistance mutations acquisition through greater clonal diversity is thought to be associated with TP53 mutation-related genomic instability [94, 95]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.